{"metadata": {"source": "pubchem", "title": "Naltrexone | C20H23NO4 | CID 5360515 - PubChem", "description": "Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5360515", "drug": "Naltrexone", "cid": 5360515, "char_count": 126230, "word_count": 16119, "doc_id": "doc_41", "num_chunks": 179, "chunk_id": "41::chunk_98", "document_index": 41, "latency_s": 1.4472142000013264, "prompt_toks": 33656, "completion_toks": 95, "relevance_score": 0.02433019}, "content": "Drug: Naltrexone | cid: 5360515\nSource: pubchem | Source description: Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Naltrexone should not be administered with thioridazine due to the risk of lethargy and somnolence.\n\nMainstreaming Addiction Treatment (MAT) Act\n\nThe Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and integrate substance use disorder treatment across healthcare settings.\n\n\n                    Context: \n                    This excerpt discusses drug interaction warnings and recent regulatory developments related to naltrexone. It highlights a specific contraindication with thioridazine due to safety risks and provides an overview of the Mainstreaming Addiction Treatment (MAT) Act, which aims to expand access to opioid use disorder treatments by broadening provider prescribing rights for medications like buprenorphine. This information is relevant for understanding safety precautions and evolving policies surrounding naltrexone and related therapies.\n                "}
{"metadata": {"source": "pubchem", "title": "Naltrexone | C20H23NO4 | CID 5360515 - PubChem", "description": "Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5360515", "drug": "Naltrexone", "cid": 5360515, "char_count": 126230, "word_count": 16119, "doc_id": "doc_41", "num_chunks": 179, "chunk_id": "41::chunk_98", "document_index": 41, "latency_s": 1.4472142000013264, "prompt_toks": 33656, "completion_toks": 95, "relevance_score": 0.02433019}, "content": "Drug: Naltrexone | cid: 5360515\nSource: pubchem | Source description: Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Naltrexone should not be administered with thioridazine due to the risk of lethargy and somnolence.\n\nMainstreaming Addiction Treatment (MAT) Act\n\nThe Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and integrate substance use disorder treatment across healthcare settings.\n\n\n                    Context: \n                    This excerpt discusses drug interaction warnings and recent regulatory developments related to naltrexone. It highlights a specific contraindication with thioridazine due to safety risks and provides an overview of the Mainstreaming Addiction Treatment (MAT) Act, which aims to expand access to opioid use disorder treatments by broadening provider prescribing rights for medications like buprenorphine. This information is relevant for understanding safety precautions and evolving policies surrounding naltrexone and related therapies.\n                "}
{"metadata": {"source": "pubchem", "title": "Naltrexone | C20H23NO4 | CID 5360515 - PubChem", "description": "Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5360515", "drug": "Naltrexone", "cid": 5360515, "char_count": 126230, "word_count": 16119, "doc_id": "doc_41", "num_chunks": 179, "chunk_id": "41::chunk_99", "document_index": 41, "latency_s": 1.2226388000126462, "prompt_toks": 33665, "completion_toks": 82, "relevance_score": 0.0029008577}, "content": "Drug: Naltrexone | cid: 5360515\nSource: pubchem | Source description: Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if applicable state law permits, and SAMHSA encourages them to do so. Prescribers registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed from registrants.\n\nThere are no longer limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required.\n\n\n                    Context: \n                    This excerpt details recent regulatory changes introduced by the MAT Act as of December 2022, eliminating the DATA-Waiver program and expanding prescribing authority for buprenorphine to all DEA-registered Schedule III practitioners. It emphasizes the removal of patient treatment limits and tracking requirements, highlighting updates relevant to medication regulation and prescribing practices discussed within the comprehensive chemotherapeutic and pharmacological information on naltrexone.\n                "}
